About Seipin
Seipin (BSCL2) is a protein
from Homo sapiens identified by UniProt accession
Q96G97, 398 residues long.
MolForge cross-references it against 0 known binders and
184 disease associations.
Target properties
| Protein name | Seipin |
| UniProt accession | Q96G97 |
| Gene | BSCL2 |
| Organism | Homo sapiens |
| Length | 398 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (184)
Diseases linked to this target (Open Targets).
- congenital generalized lipodystrophy type 2 · score 0.75
- neuronopathy, distal hereditary motor, type 5C · score 0.74
- severe neurodegenerative syndrome with lipodystrophy · score 0.74
- hereditary spastic paraplegia 17 · score 0.74
- Autosomal dominant spastic paraplegia type 17 · score 0.72
- neuronopathy, distal hereditary motor, type 5A · score 0.56
- Charcot-Marie-Tooth disease type 2 · score 0.55
- genetic disorder · score 0.49
- Distal hereditary motor neuropathy type 5 · score 0.46
- hereditary spastic paraplegia · score 0.42
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q96G97-F1 | alphafold | PREDICTED | 74.00 | — |
Amino-acid sequence (398 residues)
MVNDPPVPAL LWAQEVGQVL AGRARRLLLQ FGVLFCTILL LLWVSVFLYG SFYYSYMPTV SHLSPVHFYY RTDCDSSTTS LCSFPVANVS LTKGGRDRVL MYGQPYRVTL ELELPESPVN QDLGMFLVTI SCYTRGGRII STSSRSVMLH YRSDLLQMLD TLVFSSLLLF GFAEQKQLLE VELYADYREN SYVPTTGAII EIHSKRIQLY GAYLRIHAHF TGLRYLLYNF PMTCAFIGVA SNFTFLSVIV LFSYMQWVWG GIWPRHRFSL QVNIRKRDNS RKEVQRRISA HQPGPEGQEE STPQSDVTED GESPEDPSGT EGQLSEEEKP DQQPLSGEEE LEPEASDGSG SWEDAALLTE ANLPAPAPAS ASAPVLETLG SSEPAGGALR QRPTCSSS
Explore Seipin with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets